Palvella Therapeutics (PVLA) Gross Profit (2013 - 2014)
Palvella Therapeutics (PVLA) reported Gross Profit of $18706.0 for Q3 2014, up 155983.33% year-over-year from N/an in Q3 2013, and up 52061.11% on a QoQ basis from -$36.0 in Q4 2013.
Palvella Therapeutics (PVLA) has 2 years of Gross Profit data on file, last reported at $18706.0 in Q3 2014.
- Quarterly Gross Profit rose 155983.33% year-over-year to $18706.0 in Q3 2014, while the trailing twelve-month figure through Sep 2014 was $18658.0 (changed N/A YoY) and the FY2013 annual result came in at $5.2 million, changed N/A from the prior year.
- Gross Profit improved to $18706.0 in Q3 2014 per PVLA's latest filing, from -$36.0 in the prior quarter.
- Across five years, Gross Profit topped out at $18706.0 in Q3 2014 and bottomed at -$36.0 in Q4 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 18,706.00 |
| Sep 30, 2014 | 18,706.00 |
| Dec 31, 2013 | -36.00 |
| Dec 31, 2013 | -36.00 |
| Sep 30, 2013 | -12.00 |
| Sep 30, 2013 | -12.00 |